Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBD09 in Combination With Other Active Agents in Adults With Drug-Sensitive Pulmonary Tuberculosis
NCT07525427Phase 2Recruiting
- Sponsor
- Gates Medical Research Institute
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MK-7762 in pulmonary tuberculosis (TB), sponsored by Gates Medical Research Institute. Started Apr 2026; status: recruiting.
02
Drugs
MK-7762
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT07525427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07525427.